🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

AbCellera Biologics Inc. ABCL PHARMA

Healthcare · Biotechnology · Canada
https://www.abcellera.com
Company Profile ↓
$11.44
+149.78% 1Y
Mkt Cap$3.71B
P/E-21.19
P/B3.78
52W High$12.50
52W Low$2.78
Book Value$2.92
EPS (TTM)$-0.54

Company Overview

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.15.

Recent Developments

  • Dec 2025 Revenue of $75.13M (+160.6% YoY); net profit $-146.41M.
  • Trailing 12 Months Year-on-year growth — revenue -76.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR -46.3%, profit CAGR -64.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-46.31%
1 Year:-76.30%

Compounded Profit Growth

5 Years:-64.12%
1 Year:-

Stock Price Performance

1 Year:+149.78%
6 Months:+225.00%
3 Months:+111.07%
1 Month:+65.08%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 89% of range
$2.78 $12.50
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)61.24 · Neutral
Price Performance
1M+65.08%
3M+111.07%
6M+225.00%
1Y+149.78%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -46.3% CAGR over 5 years.
  • Earnings shrank at -64.1% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-21.19
Industry PE
24.83
Forward P/E
-16.00
PEG Ratio
-
Book Value
$2.92
Price to Book
3.78
P/S
54.11
EV/EBITDA
-15.52
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-46.31%
Profit 5Y
-64.12%
Revenue (YoY)
-76.30%
Earnings (YoY)
-

Profitability & Returns

ROCE
-15.72%
ROE
-17.30%
ROA
-10.39%
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.18
EPS (TTM)
$-0.54

Balance Sheet & Liquidity

Debt/Equity
0.15
Quick Ratio
11.23
Current Ratio
12.77
Debt
$135.62M
Total Assets
$1.31B
Current Assets
$664.60M
Working Capital
$663.92M

Ownership

Promoter Holding
21.74%
Chg in Prom Hold
-1.30%
FII / Inst Holding
36.69%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$3.71B
Total Revenue (TTM)
$66.17M
EBITDA
$-199.96M
Free Cash Flow
$-46.43M
Operating Cash Flow
$-94.94M
Shares Outstanding
324.05M
Gross Margin
-
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ABCL AbCellera Biologics Inc. PHARMA 11.44 -21.19 $3.71B 0.00% -15.72% -17.30% -46.31% -64.12%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 4.66M11.23M9.36M202.74M27.64M5.51M316.58M45.92M101.38M12.19M10.06M6.60M9.95M7.32M6.51M-4.24M17.08M8.96M44.85M8.31M4.05M
Cost of Revenue ----------------------
Gross Profit ----------------------
Operating Expenses ----------------62.74M62.98M82.50M70.12M61.49M-
Operating Income -2.12M-854.00K-1.77M158.07M-7.03M-28.10M224.95M-8.40M37.73M-64.87M-51.39M-54.89M-54.89M-93.45M-93.66M--58.51M-45.89M-73.55M-25.27M-53.18M-62.78M
EBITDA -----------------51.90M-38.83M-66.31M-17.35M-44.52M-
Interest Expense ----------------------
Pretax Income -----------------52.98M-36.34M-68.77M-19.50M-49.54M-
Tax Provision -----------------7.36M-1.62M-11.65M-10.55M-6.37M-
Net Income -2.09M6.70M-2.69M117.22M-2.32M-21.38M168.57M-6.79M26.62M-40.11M-30.53M-28.61M-40.61M-36.93M-51.11M--45.62M-34.73M-57.12M-8.95M-43.16M-55.43M
Diluted EPS -0.010.03-0.020.37-0.01-0.080.54-0.020.08-0.14-0.11-0.10-0.14-0.13-0.17--0.15-0.12-0.19--0.14-0.18
R&D Expense 4.12M9.14M7.50M12.35M15.05M17.45M26.37M26.68M26.58M52.65M36.47M37.92M39.29M40.93M40.97M-42.50M39.21M55.03M-46.66M45.99M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 11.61M233.16M-485.42M38.02M28.83M75.13M
Cost of Revenue --45.52M66.44M00-
Gross Profit --329.69M418.99M38.02M28.83M-
Operating Expenses ---191.92M261.08M329.98M278.34M
Operating Income -4.12M156.03M-227.06M-223.05M-301.15M-203.21M
EBITDA ---260.17M-192.16M-204.15M-174.39M
Interest Expense --5.22M4.04M---
Pretax Income ---239.10M-174.03M-200.40M-177.59M
Tax Provision ---80.58M-27.63M-37.54M-31.18M
Net Income -2.21M118.92M-158.52M-146.40M-162.86M-146.41M
Diluted EPS -0.010.45-0.50-0.51-0.55-0.49
R&D Expense 10.11M29.39M62.06M107.88M175.66M167.26M186.83M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --1.01B-1.54B1.49B1.36B1.36B
Current Assets ----1.03B871.99M751.37M728.23M
Cash & Equivalents --594.12M-386.54M133.32M156.32M128.51M
Inventory ----1.53M1.11M06.34M
Receivables ----38.59M30.59M33.62M58.29M
Total Liabilities --175.03M-307.63M335.78M304.47M390.05M
Current Liabilities --103.49M-118.32M119.01M76.61M64.31M
Long Term Debt --------
Total Debt ----82.26M77.38M65.36M143.22M
Total Equity 11.61M10.25M830.51M-1.23B1.15B1.06B966.90M
Shares Outstanding ----286.85M290.82M295.76M300.60M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 2.69M22.69M-277.36M-43.88M-108.56M-131.29M
Investing Cash Flow -5.78M-119.78M--352.62M-221.11M121.41M87.75M
Financing Cash Flow 195.00K683.65M--1.63M10.36M12.77M14.08M
Capital Expenditure -4.00M-9.67M--72.66M-76.95M-78.40M-42.77M
Free Cash Flow -1.30M13.02M-204.70M-120.82M-186.95M-174.07M
Net Change in Cash ----76.89M-254.63M25.62M-29.46M

Ratios (Annual)

Figures in %.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---86.3%100.0%100.0%-
Operating Margin % -35.5%66.9%-46.8%-586.6%-1,044.4%-270.5%
Net Margin % -19.0%51.0%-32.7%-385.0%-564.8%-194.9%
ROE % -21.6%14.3%-12.9%-12.7%-15.4%-15.1%
ROCE % -17.3%-16.0%-16.3%-23.5%-15.7%

Shareholding Pattern

Insiders
21.74%
Institutions
36.69%
Public Float
46.88%

Top Institutional Holders

#Holder% HeldSharesValue
1 Baker Bros. Advisors, LP 10.77% 33.01M $416.94M
2 Capital World Investors 4.43% 13.59M $171.62M
3 Two Sigma Investments, LP 3.40% 10.44M $131.82M
4 TD Waterhouse Canada Inc. 3.12% 9.57M $120.85M
5 Bank of America Corporation 2.00% 6.14M $77.57M
6 UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 1.41% 4.32M $54.53M
7 ArrowMark Colorado Holdings LLC 1.34% 4.11M $51.85M
8 Blackrock Inc. 1.24% 3.81M $48.06M
9 Driehaus Capital Management, LLC 0.93% 2.86M $36.18M
10 Tudor Investment Corp Et Al 0.67% 2.06M $26.06M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ABCL

Yahoo Finance Fri, 14 Aug 2026

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune disease…

Yahoo Finance hu, 13 Aug 2026

AbCellera (ABCL) Q2 2026 Earnings Call Transcript

Lead program ABCL635 Phase 2 enrollment complete with data expected in August.

Yahoo Finance Wed, 12 Aug 2026

AbCellera Biologics (ABCL) Is Up 60.3% After Strong Phase 2 Menopause Data For ABCL635 - Has The Bull Case Changed?

AbCellera Biologics recently reported that its investigational antibody ABCL635 achieved statistically significant Phase 2 results, with a single 600 mg subcutaneous dose reducing both the frequency and severity of moderate-to-severe menopa…

Yahoo Finance Wed, 12 Aug 2026

AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal

The latest analyst update on AbCellera Biologics reflects a higher Fair Value estimate of US$14.63 compared with the prior figure of US$10.43. This shift aligns with more constructive Street research that follows recent clinical data and ne…

Yahoo Finance ue, 11 Aug 2026

AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 Results

Why ABCL635’s Phase 2 data matters for AbCellera Biologics stock AbCellera Biologics (ABCL) has become a focus for many biotech investors after announcing that ABCL635 met primary endpoints in a Phase 2 trial for menopause related hot flash…

Yahoo Finance ue, 11 Aug 2026

Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?

AbCellera, Replimune and Airbnb reached fresh highs as strong drug data, new funding and better-than-expected earnings boosted investor confidence.

ABCL — Frequently Asked Questions

What is the current share price of AbCellera Biologics Inc. (ABCL)?

As of 2026-09-19 21:16 PDT, AbCellera Biologics Inc. (ABCL) trades at $11.44 on NasdaqGS. Its 52-week range is $2.78 to $12.50.

What is the market capitalisation of ABCL?

AbCellera Biologics Inc. (ABCL) has a market capitalisation of $3.71B on NasdaqGS.

What is the P/E ratio of ABCL?

ABCL trades at a trailing price-to-earnings (P/E) ratio of -21.19. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.78.

What is the return on equity (ROE) of ABCL?

ABCL has a return on equity (ROE) of -17.30%. Its return on capital employed (ROCE) is -15.72%.

Is ABCL a good stock to buy?

This page provides a data-driven analysis of AbCellera Biologics Inc. (ABCL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space